Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,555 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lipid Peroxidation Regulators GPX4 and FSP1 as Prognostic Markers and Therapeutic Targets in Advanced Gastric Cancer.
Tamura K, Tomita Y, Kanazawa T, Shinohara H, Sakano M, Ishibashi S, Ikeda M, Kinoshita M, Minami J, Yamamoto K, Kato Y, Furukawa A, Haruki S, Tokunaga M, Kinugasa Y, Kurata M, Kitagawa M, Ohashi K, Yamamoto K. Tamura K, et al. Among authors: tomita y. Int J Mol Sci. 2024 Aug 24;25(17):9203. doi: 10.3390/ijms25179203. Int J Mol Sci. 2024. PMID: 39273151 Free PMC article.
GPX4 and FSP1 Expression in Lung Adenocarcinoma: Prognostic Implications and Ferroptosis-Based Therapeutic Strategies.
Takahara H, Kanazawa T, Oshita H, Tomita Y, Hananoi Y, Ishibashi S, Ikeda M, Furukawa A, Kinoshita M, Yamamoto K, Kato Y, Ishibashi H, Okubo K, Kurata M, Kitagawa M, Ohashi K, Yamamoto K. Takahara H, et al. Among authors: tomita y. Cancers (Basel). 2024 Nov 20;16(22):3888. doi: 10.3390/cancers16223888. Cancers (Basel). 2024. PMID: 39594843 Free PMC article.
Prognostic significance and therapeutic potential of guanosine triphosphate cyclohydrolase 1 in esophageal squamous cell carcinoma: clinical implications of ferroptosis and lipid peroxidation regulation.
Sakano M, Tomita Y, Kanazawa T, Ishibashi S, Ikeda M, Oshita H, Hananoi Y, Kato Y, Yamamoto K, Furukawa A, Kinoshita M, Haruki S, Tokunaga M, Kinugasa Y, Kurata M, Kitagawa M, Ohashi K, Yamamoto K. Sakano M, et al. Among authors: tomita y. Front Oncol. 2024 Dec 11;14:1459940. doi: 10.3389/fonc.2024.1459940. eCollection 2024. Front Oncol. 2024. PMID: 39723384 Free PMC article.
Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial.
Tucker M, Chen YW, Voss MH, McGregor BA, Bilen MA, Grimm MO, Nathan P, Kollmannsberger C, Tomita Y, Huang B, Amezquita R, Mariani M, di Pietro A, Rini B. Tucker M, et al. Among authors: tomita y. BMJ Oncol. 2024 Jun 12;3(1):e000181. doi: 10.1136/bmjonc-2023-000181. eCollection 2024. BMJ Oncol. 2024. PMID: 39886142 Free PMC article.
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia.
Chung HJ, Kondoh C, Bae WK, Tamada S, Matsubara N, Lee HJ, Mizuno R, Anai S, Kimura G, Tomita Y, Chang CH, Chang JW, Lin J, Perini RF, Molife LR, Powles T, Rini BI, Uemura H. Chung HJ, et al. Among authors: tomita y. Jpn J Clin Oncol. 2025 Jan 16:hyae182. doi: 10.1093/jjco/hyae182. Online ahead of print. Jpn J Clin Oncol. 2025. PMID: 39815637
2,555 results